FGFR3 and neoplasm: FGFR3 activation concurrently contributes to cell survival of Ctx-naive EGFR ligands-positive SCC tumour cells challenged to Ctx at first, thus limiting its activity and likely promoting their own resistance if Ctx-induced blockade of EGFR-ligands signalling persists.